A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Sponsor: Eli Lilly and Company
This PHASE3 trial investigates Alzheimer Disease and is currently ongoing. Eli Lilly and Company leads this study, which shows 42 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
42 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Nov 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
▶ Show 37 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .